FDA granted accelerated approval to omacetaxine mepesuccinate, (SYNRIBO for Injection, for subcutaneous use, Teva Pharmaceutical Industries Ltd.), for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). October 26, 2012.

More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm325990.htm